Lost Illusions: A Candid Look Inside NIH Peer Review
I spent more than a decade serving on federal scientific review panels, where my fellow panelists were dedicated, rigorous experts. Yet the process was far less impersonal, systematic, and insulated from personal or political influence than its defenders often claim.
This perspective is vital today as the Trump administration’s Office of Management and Budget (OMB) has proposed allowing senior political appointees to conduct a “pre-issuance review” of all discretionary NIH grants. Such a mechanism would enable political officials to scrutinize scientific proposals before funding decisions are finalized. And once established, this process would not be limited to the current administration, but accessible to all future administrations—each with its own priorities, alliances, and agendas.
Yet opposing political interference does not equate to idealizing the existing system. The editors of the New England Journal of Medicine (NEJM) highlighted valid concerns about politicization of science in their critique, but their argument was weakened by oversimplifying the current peer review process.
The conventional narrative describes NIH review as a process where objective experts evaluate proposals purely on scientific merit, with the strongest applications receiving funding. This is partly accurate, but incomplete.
In reality, while panel members assess applications and submit scores, the final funding decisions involve multiple layers—advisory councils, program officers, and institute leadership. NIH institutes weigh scientific merit against programmatic priorities and institutional objectives. Some even utilize “select pay” to support applications above the payline that align with strategic research goals.
The NEJM editors likely understand this nuance. The idealized account serves their rhetorical purpose better than the truth.
Political discretion has always been part of the NIH funding landscape, a reality the NEJM editors cannot plausibly ignore.
The standard review approach often involves limited close reading of applications by primary reviewers, with panel members participating in discussions without reading the proposals. This dynamic significantly impacts outcomes, as assigned reviewer biases or misunderstandings can lead to erroneous decisions. A poor reviewer assignment can be detrimental for junior investigators and setbacks for senior colleagues alike.
Empirical evidence supports concerns about objectivity. Research evaluating multiple reviewers’ opinions on the same funded grants revealed minimal agreement, demonstrating the inherent subjectivity in determining scientific merit. This lack of consensus reflects the challenging threshold between exceptional and strong proposals, highlighting the numerous random factors influencing outcomes.
A more honest approach to the OMB proposal must begin with recognizing these inherent limitations. NIH Director Dr. Jay Bhattacharya has previously called for greater transparency in balancing scientific merit with mission requirements and programmatic considerations, as well as promoting research on replication and null results that traditional metrics often overlook.
However, formalizing political pre-issuance review offers no solution. This would mistakenly treat existing human discretion as justification for direct political control over scientific funding. The core issue isn’t excessive scientist insulation from politics, but rather the system’s tendency to mask subjective judgments as objective scientific assessments.
The debate shouldn’t be between a perfect scientific meritocracy and Soviet-style Lysenkoism. Rather, we must choose between strengthening our flawed but valuable system or creating one more overtly susceptible to political control by this or any administration.
The true concern isn’t some new scientific equivalent of Lysenko being funded, but the real danger of promising young researchers receiving grants based on political calculations. The central scandal isn’t solely politics corrupting science—it’s a system already overly accessible to insiders potentially becoming equally accessible to politicians.
In truth, the stakes are about integrity and innovation. We must prioritize maintaining public trust in systemic impartiality while driving meaningful reform. The discussion should focus on balancing necessary scientific rigor with essential portfolio adjustments, determining how much funding should be allocated to promising new areas versus established research programs, and implementing robust conflict-of-interest measures that don’t compromise the unique perspectives each application deserves.
